secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001104659-25-041204
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics restructures, reduces workforce 20% to focus on Duchenne MD candidates
--------------------------------------------------------------------------------

- Board approved strategic plan on April 29, 2025; workforce reduction of approximately 20% effective May 2.
- Estimated $2 million in total charges (severance, healthcare) primarily in Q2 2025.
- Company prioritizing DMD candidates ENTR-601-44, -45, -50, -51 and ocular programs.
- Anticipates cost savings to extend cash runway into Q2 2027.
- Workforce reduction substantially completed by end of Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/0001104659-25-041204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/tm2513421d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-041204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer